Litcius/Paper detail

ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer

Yang Xiao, Fang‐Tsyr Lin, Weei-Chin Lin

2021Proceedings of the National Academy of Sciences79 citationsDOIOpen Access PDF

Abstract

gene is often seen in lung squamous cell carcinoma, ovarian cancer, and esophageal cancer, but its significance remains to be fully determined. Here we identify ACTL6A overexpression as a novel cause for platinum resistance. High levels of ACTL6A are associated with chemoresistance in several types of human cancer. We show that overexpression of ACTL6A leads to increased repair of cisplatin-DNA adducts and resistance to cisplatin treatment. In contrast, depletion of ACTL6A inhibits the repair of cisplatin-induced DNA lesions, and increases cisplatin sensitivity in cisplatin-resistant ovarian cancer cells. The regulation of repair by ACTL6A is mediated through the SWI/SNF chromatin remodeling complex. Treatment with a histone deacetylase inhibitor can reverse the effect of ACTL6A overexpression on the repair of cisplatin-induced DNA damage and render cancer cells more sensitive to cisplatin treatment in a xenograft mouse model. Taken together, our study uncovers a novel role for ACTL6A in platinum resistance, and provides evidence supporting the feasibility of using HDAC inhibitors for platinum resistant tumors.

Topics & Concepts

CisplatinDNA repairCancer researchDNA damageChromatin remodelingChromatinHistoneCancerOvarian cancerNucleotide excision repairCancer cellLung cancerHistone deacetylaseBiologyChemistryMedicineDNAChemotherapyInternal medicineGeneticsChromatin Remodeling and CancerGenomics and Chromatin DynamicsHistone Deacetylase Inhibitors Research